胰高血糖素樣肽-1（GLP-1）是小腸消化食物時(shí)L細(xì)胞分泌的一種促胰島素激素，可以促進(jìn)胰島素分泌，從而維持葡萄糖穩(wěn)態(tài)，其受體廣泛分布于胰島、心臟、肺、皮膚等器官中。利拉魯肽是一種長(zhǎng)效的GLP-1類似物，目前被廣泛用于治療2型糖尿病。近年來(lái)研究發(fā)現(xiàn)，利拉魯肽在肥胖癥、神經(jīng)系統(tǒng)疾病、心血管系統(tǒng)疾病中均發(fā)揮有益作用。對(duì)利拉魯肽治療糖尿病、肥胖癥、神經(jīng)系統(tǒng)疾病、心血管系統(tǒng)疾病和精神疾病等的臨床研究及其作用機(jī)制進(jìn)行綜述，旨在為拓展和開(kāi)發(fā)利拉魯肽類藥物的臨床應(yīng)用提供新思路。

Glucagon-like peptide-1 is an insulin-stimulating hormone secreted by L cells while the small intestine digests food. It can promote insulin secretion to maintain glucose homeostasis. The receptors are widely distributed in organs, such as pancreatic islets, heart, lungs, and skin. As a long-acting GLP-1 analogue, liraglutide has recently become the first-line treatment for type 2 diabetes mellitus. Recently, studies have found that liraglutide plays a beneficial role in obesity, neurodegenerative diseases, cardiovascular diseases, and so on. This review article summarizes its application and mechanism of liraglutide, and aims to provide novel ideas for the expansion and development of the clinical application of liraglutide.

R977

國(guó)家自然科學(xué)基金資助項(xiàng)目（81573431，81971326，82070236）